Vanguard Fiduciary Trust
LTRN icon

Vanguard Fiduciary Trust’s Lantern Pharma LTRN Stock Holding History

Vanguard Fiduciary Trust’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Buy
49,950
+343
+0.7% +$1.01K ﹤0.01% 3564
2026
Q1 		$68K Buy
+49,607
New +$139K ﹤0.01% 3776

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Vanguard Fiduciary Trust's LTRN Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Lantern Pharma (LTRN) stake by 0.69% in Q2 2026, buying an estimated $1.01K and bringing the position to 49,950 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #3564.

Vanguard Fiduciary Trust first reported a position in LTRN in Q1 2026 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Vanguard Fiduciary Trust held 49,950 shares of Lantern Pharma worth $208K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 343 Lantern Pharma shares in Q2 2026, an estimated $1.01K.
  • Lantern Pharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3564 holding.
  • Vanguard Fiduciary Trust first reported a position in Lantern Pharma in Q1 2026 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.